<?xml version="1.0" encoding="UTF-8"?>
<p id="P84">Telbivudine-triphosphate inhibits HBV by competitive inhibition of viral DNA polymerase. Oral telbivudine is approved for the treatment of CHB in patients with compensated liver disease and evidence of active viral replication, persistently increased serum ALT concentrations, and histologic evidence of active liver inflammation and fibrosis.
 <sup>
  <xref ref-type="bibr" rid="R180">180</xref>,
  <xref ref-type="bibr" rid="R181">181</xref>
 </sup> It is considered more effective than lamivudine and adefovir.
 <sup>
  <xref ref-type="bibr" rid="R182">182</xref>,
  <xref ref-type="bibr" rid="R183">183</xref>
 </sup> Compared with lamivudine, telbivudine was associated with a higher degree of reduction in HBV DNA levels; however, no significant differences were found in ALT level normalization, loss of HBeAg, or anti-HBe seroconversion.
</p>
